Showing results (111-120 of 466) with videos related to
Sort By:
Pageof 47
Stroke|August 5, 2006
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertensionBen Ariff, Andrew Zambanini, Sarita Vamadeva, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 30, 2022
The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19Ewan McFarlane, Marijke Linschoten, Folkert W Asselbergs, et al.Journal of Nursing Measurement|June 22, 2013
Parental Human Papillomavirus Vaccine Survey (PHPVS): nurse-led instrument development and psychometric testing for use in research and primary care screeningTami Lynn Thomas, Ora L Strickland, Ralph DiClemente, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|August 4, 2012
Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exerciseBryan Williams, Fabio Baschiera, Peter S Lacy, et al.Optics Express|June 6, 2019
Sub-surface imaging of soiled cotton fabric using full-field optical coherence tomographyZijian Zhang, Uyai Ikpatt, Samuel Lawman, et al.Journal of Hypertension|January 10, 2025
Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registryAlejandro de la Sierra, Luis M Ruilope, Natalie Staplin, et al.Journal of Hypertension|April 14, 2012
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyAnne Christine H Ruwald, Bo Westergaard, Thomas Sehestedt, et al.Circulation|March 15, 2006
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension StudyPeter M Okin, Richard B Devereux, Eva Gerdts, et al.Journal of the American College of Cardiology|March 1, 2005
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyKristian Wachtell, Mika Lehto, Eva Gerdts, et al.Journal of Hypertension|September 18, 2015
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudyJulie K K Vishram, Björn Dahlöf, Richard B Devereux, et al.Pageof 47